🔗 Share this article

As America undertakes historic changes to its immunization recommendations, an unexpected name has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her recent position at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Agency leaders were set to announce radical changes to the childhood vaccine schedule in December, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of alignment with much of the international standard with little proof for public health gain. This reveal has been delayed until the new year.

Rather than Vinay Prasad, Dr. Høeg is listed to present at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US in order to be more like Denmark, a country with universal health coverage and a population roughly the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

Høeg has little discernible background in drug development, approval processes or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for running the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran CBER have had.”

This division has an enormous range of responsibilities at the FDA, the former commissioner stated.

“Many people just focuses on the new drug program, but the off-patent medication office clears numerous generic medications. There’s a biosimilars division, over-the-counter program and other areas, and each of these must be looked after,” she noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a significant management component to the role, which manages more than 5,000 employees. “It’s a huge management job, if you do it right,” the former official said.

Agency Reaction and Disputed Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among agency officials on vaccines, a press secretary responded that the “questions rely on incorrect presumptions”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson stated, citing the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a contentious expedited medication authorization process that allegedly troubled her former heads. “By what process are these therapies being chosen for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards laxer rules of all drugs, with the exception of vaccines.”

Documented Track Record on Immunizations

Regarding vaccines, Høeg has a more documented, if problematic, track record, critics have noted. She published a research paper using unconfirmed public submissions to estimate the rate of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the current administration included revising regulations for novel immunizations and ending “optional” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has allegedly proposed preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who commences with her preconceived notions and reverse-engineers to retrofit the data in a very misleading, untruthful manner,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|